Innoviva partners with Dr Reddys across four territories
Share
- Innoviva Specialty Therapeutics entered an exclusive distribution and licensing agreement with Dr. Reddy's Laboratories for antibiotic XACDURO.
- Following the announcement, shares of parent firm Innoviva traded down at $22.50.
- Dr. Reddy's Laboratories will spearhead development and commercialization across South America, Central America, the Caribbean, and Russia.
Innoviva (NASDAQ:INVA) partnered with Dr. Reddy’s Laboratories (NYSE:RDY) to commercialize antibiotic XACDURO across four international territories.
The drug targets Acinetobacter, which the World Health Organization classifies as a critical threat pathogen on its priority list.
Dr. Reddy's will manage all regional development and regulatory filings while paying upfront fees, milestones, and tiered royalties.
Innoviva retains all commercial drug rights in unlicensed territories to maintain its primary focus on disciplined domestic execution.
The U.S. Food and Drug Administration originally approved the intravenous treatment in May 2023 for adults over 18.
More from United States
Lamar raises 2026 AFFO outlook to $8.97
Lemonade posts $336 million Q3 revenue, narrows loss
BD reveals $5.27 billion Q4 revenue, raises 2027 outlook
Cummins earnings surge to $1.14 billion as sales climb 13%
Six Flags reveals $1.17 billion Q3 revenue amid $366 million loss
EPAM Systems reports $1.43B Q3 revenue, expands buyback to $1.8B
